Study: VMA resolved in more patients who received ocriplasmin than sham treatment

NEW ORLEANS — A greater proportion of patients receiving ocriplasmin achieved vitreomacular adhesion resolution at day 28, the primary endpoint of the MIVI-005 study, compared with patients receiving sham injections, a presenter said here. Of the 100 patients in the double-masked multicenter study, 24.3% in the ocriplasmin group achieved VMA resolution compared with 12% in the sham group, Roger L. Novack, MD, PhD, FACS, said at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting. “This was not statistically significant, but it’s important to note that this was a (Read more...)

Full Story →